search
Back to results

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics (EmDia)

Primary Purpose

Diabetes Mellitus, Type 2, Diastolic Dysfunction

Status
Completed
Phase
Phase 4
Locations
Germany
Study Type
Interventional
Intervention
Empagliflozin
Placebo
Sponsored by
Johannes Gutenberg University Mainz
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring empagliflozin, diastolic function, poorly controlled type 2 diabetes mellitus

Eligibility Criteria

18 Years - 84 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects meeting all of the following criteria at visit 0 (screening) will be considered for admission to the trial:

  • Diagnosis of type 2-diabetes mellitus with stable glucose-lowering background therapy and/or dietetic treatment for at least 12 weeks
  • In subjects without glucose-lowering background therapy: the application of Metformin was considered to be unsuitable due to drug intolerance
  • HbA1c level of ≥6.5% and ≤10.0% at visit 0 (screening) for subjects on antidiabetic background therapy or HbA1c level of ≥6.5% and ≤9.0% for drug-naïve subjects with dietetic treatment
  • Diastolic cardiac dysfunction E/E' ratio ≥8 (2D-echocardiography)
  • Age 18 - 84 years
  • BMI ≤ 45 kg/m² (Body Mass Index)
  • For women: post-menopausal for more than 12 months without an alternative medical cause can participate in the trial. Women with childbearing potential can only participate, if they are surgically sterile or a negative pregnancy test (serum or urine) is available at visit 1 and they are willing to practice highly effective birth control method during trial. Reliable highly effective contraception comprises

    • combined (estrogen and progesteron containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    • progesteron-only hormonal contraception associated with inhibition of ovaluation (oral, injectable, implantable)
    • intrauterine device (IUD)
    • intrauterine hormone-releasing system (IUS)
    • bilateral tubal occlusion
    • vasectomised partner (provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success)
    • sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
  • Ability of subject to understand nature, importance and individual consequences of clinical trial
  • Signed and dated informed consent of the subject must be available before start of any specific trial procedures which is consistent with ICH-GCP guidelines and local legislation

Exclusion Criteria:

Subjects presenting with any of the following criteria at visit 0 (screening) will not be included in the trial:

  • Pretreatment with empagliflozin or other SGLT2 inhibitor within the last 3 months
  • Pretreatment with known inducers of UGT enzymes
  • Uncontrolled hyperglycemia with a glucose level > 240 mg/dl (>13.3 mmol/L) after an overnight fast
  • Impaired renal function, defined as eGFR <45 ml/min/1.73 m² of body-surface-area
  • End-stage renal failure or dialysis
  • Severe hepatic dysfunction, defined by serum levels of either SGPT, SGOT, or alkaline phosphatase above 3 x upper limit of normal (ULN)
  • Acute urinary tract infection (UTI)
  • Known acute genital infection (GI)
  • Symptomatic hypotension
  • Hematocrit above the upper limit of the reference range
  • Hypoglycemic tendencies
  • Severe PAD (Fontaine classification Stage IIb - IV)
  • Medical history of cancer and/or treatment for cancer within the last 5 years, subjects basalioma can be included in the study
  • Medical history of pancreatitis or surgery on pancreas
  • Known ketoacidosis (in the past)
  • Acute febrile disease
  • NYHA classification III - IV
  • Pregnant and/or nursing women at visit 1 (baseline)
  • Acute coronary syndrome, stroke or TIA within the last 2 months
  • Planned cardiac surgery or angioplasty within 3 months
  • Gastrointestinal surgeries that induce chronic malabsorption
  • Blood dyscrasia or any disorders causing hemolysis or unstable Red Blood Cells (e.g. malaria, babesiosis, hemolytic anemia)
  • History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
  • Alcohol or drug abuse within the last 3 months that would interfere with trial participation
  • Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial (at visit 0 (screening) or at visit 1 (baseline))
  • Medical condition that does not allow enrollment in the trial at visit 1 (baseline)
  • Current treatment with systemic steroids or change in dosage of thyroid hormones within the last 6 weeks or any other uncontrolled endocrine disorder except type 2 diabetes mellitus
  • Hereditary glucose intolerance, galactose intolerance, Lapp-lactase deficiency or glucose-galactose-malabsorption
  • Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial or participating in another trial (involving an investigational drug and/or follow-up)

Sites / Locations

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kardiologie, Präventive Kardiologie und Medizinische Prävention

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Empagliflozin

Placebo

Arm Description

10 mg Empagliflozin daily per os for 12 weeks

amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks

Outcomes

Primary Outcome Measures

difference in E/E' ratio between 12 weeks after baseline and at baseline
difference in E/E' ratio (noninvasive surrogate marker for left ventricular diastolic function (LVEDP) measured by 2D-echocardiography) between 12 weeks after baseline and at baseline

Secondary Outcome Measures

difference in E/E' ratio (change from baseline (V1) to 1 week follow-up)
difference in E/E' ratio (change from baseline (V1) to 1 week follow-up (2D-echocardiography)
difference in Left ventricular systolic function (LVEF)
difference in Left ventricular systolic function (LVEF) from baseline to week 1
difference in Left ventricular systolic function (LVEF)
difference in Left ventricular systolic function (LVEF) from baseline to week 12
difference in Left end-diastolic volume (LEDV)
difference in Left end-diastolic volume (LEDV) from baseline to week 1
difference in Left end-diastolic volume (LEDV)
difference in Left end-diastolic volume (LEDV) from baseline to week 12
difference in Carotid-femoral pulse wave velocity
difference in Carotid-femoral pulse wave velocity (cf-PWV, vascular explorer - calculated) from baseline to week 1
difference in Carotid-femoral pulse wave velocity
difference in Carotid-femoral pulse wave velocity (cf-PWV, vascular explorer - calculated) from baseline to week 12
difference in Augmentation index (AIx)
difference in Augmentation index (AIx, vascular explorer) from baseline to week 1
difference in Augmentation index (AIx)
difference in Augmentation index (AIx, vascular explorer) from baseline to week 12
difference in Arterial stiffness index (SI)
difference in Arterial stiffness index (SI, photo plethysmography) from baseline to week 1
difference in Arterial stiffness index (SI)
difference in Arterial stiffness index (SI, photo plethysmography) from baseline to week 12
difference in Reflection index
difference in Reflection index (photo plethysmography) from baseline to week 1
difference in Reflection index
difference in Reflection index (photo plethysmography) from baseline to week 12
difference in Brain natriuretic peptide (BNP)
difference in Brain natriuretic peptide (BNP) from baseline to week 1
difference in Brain natriuretic peptide (BNP)
difference in Brain natriuretic peptide (BNP) from baseline to week 12
difference in High sensitive troponin I (hs TnI)
difference in High sensitive troponin I (hs TnI) from baseline to week 1
difference in High sensitive troponin I (hs TnI)
difference in High sensitive troponin I (hs TnI) from baseline to week 12
difference in High sensitive C-reactive protein (hs CRP)
difference in High sensitive C-reactive protein (hs CRP) from baseline to week 1
difference in High sensitive C-reactive protein (hs CRP)
difference in High sensitive C-reactive protein (hs CRP) from baseline to week 12
difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with eGFR 45-59 ml/min/1.73 m²
difference in E/E' ratio (noninvasive surrogate marker for left ventricular diastolic function (LVEDP) measured by 2D-echocardiography) between 12 weeks after baseline and at baseline in the subgroup of patients with eGFR 45-59 ml/min/1.73 m²
difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with HbA1c 6.5%-6.9%
difference in E/E' ratio (noninvasive surrogate marker for left ventricular diastolic function (LVEDP) measured by 2D-echocardiography) between 12 weeks after baseline and at baseline in the subgroup of patients with with HbA1c 6.5%-6.9%

Full Information

First Posted
October 12, 2016
Last Updated
April 16, 2021
Sponsor
Johannes Gutenberg University Mainz
Collaborators
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT02932436
Brief Title
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
Acronym
EmDia
Official Title
A Phase IV, Single-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study on the Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Individuals With Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
October 10, 2016 (Actual)
Primary Completion Date
June 15, 2020 (Actual)
Study Completion Date
August 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johannes Gutenberg University Mainz
Collaborators
Boehringer Ingelheim

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the EmDia trial is to compare the effects of empagliflozin with placebo in addition to standard diabetic treatment or dietetic treatment on cardiac diastolic function in patients with type 2 Diabetes mellitus.
Detailed Description
Diabetes is a serious and increasing global health burden. It has been shown, that diabetes is associated with a two-fold higher risk for coronary heart disease, stroke and for the aggregate of other vascular death independently of other conventional risk factors. It is the leading cause of cardiovascular disease. Diabetes mellitus substantially increases the risk of macrovascular and microvascular complications, such as vascular dysfunction with developing coronary, cerebrovascular, and peripheral arterial disease, heart failure, nerve disorders (neuropathy), eye complications (e.g. cataracts, glaucoma diabetic retinopathy), kidney disease (nephropathy), foot ulcers, restriction of mental function, and psychosomatic diseases (e.g. stress, anxiety and depression). The most common of the cardiovascular complications in diabetics are ischemic cardiomyopathy and left ventricular (LV) dysfunction. Of particular interest here is the diastolic dysfunction, as an early sign of diabetic heart muscle disease followed by systolic damage. Although diabetes has a decisive role in the development of cardiovascular disease, traditional glucose lowering agents have failed to convincingly show that intensive glucose control significantly reduces CVD events. A new approach for treatment of adult patients with type 2 diabetes was found with the selective inhibition of sodium glucose cotransporter 2 (SGLT2). Studies have shown that empagliflozin, a potent SGLT2 inhibitor, not only effectively reduces the rates of hyperglycemia but also blood pressure and weight. (16, 18) In addition, beneficial effects on arterial stiffness and vascular resistance, visceral adiposity, albuminuria and plasma urate have been reported. The results of the EMPA-REG OUTCOME study suggest that empagliflozin added to the standard therapy has a positive influence on cardiovascular outcomes and heart failure hospitalization in individuals with diabetic mellitus. The aim of the present study is to investigate the effects of empagliflozin, in comparison with placebo, on cardiac and vascular function as well as on cardiac biomarker in individuals with type 2 diabetes with standard therapy, increased E/E' ratio and poor glycemic control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Diastolic Dysfunction
Keywords
empagliflozin, diastolic function, poorly controlled type 2 diabetes mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
144 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Empagliflozin
Arm Type
Experimental
Arm Description
10 mg Empagliflozin daily per os for 12 weeks
Arm Title
Placebo
Arm Type
Experimental
Arm Description
amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Empagliflozin
Other Intervention Name(s)
Jardiance
Intervention Description
10 mg per os daily for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
Primary Outcome Measure Information:
Title
difference in E/E' ratio between 12 weeks after baseline and at baseline
Description
difference in E/E' ratio (noninvasive surrogate marker for left ventricular diastolic function (LVEDP) measured by 2D-echocardiography) between 12 weeks after baseline and at baseline
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
difference in E/E' ratio (change from baseline (V1) to 1 week follow-up)
Description
difference in E/E' ratio (change from baseline (V1) to 1 week follow-up (2D-echocardiography)
Time Frame
1 week
Title
difference in Left ventricular systolic function (LVEF)
Description
difference in Left ventricular systolic function (LVEF) from baseline to week 1
Time Frame
1 week
Title
difference in Left ventricular systolic function (LVEF)
Description
difference in Left ventricular systolic function (LVEF) from baseline to week 12
Time Frame
12 weeks
Title
difference in Left end-diastolic volume (LEDV)
Description
difference in Left end-diastolic volume (LEDV) from baseline to week 1
Time Frame
1 week
Title
difference in Left end-diastolic volume (LEDV)
Description
difference in Left end-diastolic volume (LEDV) from baseline to week 12
Time Frame
12 weeks
Title
difference in Carotid-femoral pulse wave velocity
Description
difference in Carotid-femoral pulse wave velocity (cf-PWV, vascular explorer - calculated) from baseline to week 1
Time Frame
1 week
Title
difference in Carotid-femoral pulse wave velocity
Description
difference in Carotid-femoral pulse wave velocity (cf-PWV, vascular explorer - calculated) from baseline to week 12
Time Frame
12 weeks
Title
difference in Augmentation index (AIx)
Description
difference in Augmentation index (AIx, vascular explorer) from baseline to week 1
Time Frame
1 week
Title
difference in Augmentation index (AIx)
Description
difference in Augmentation index (AIx, vascular explorer) from baseline to week 12
Time Frame
12 week
Title
difference in Arterial stiffness index (SI)
Description
difference in Arterial stiffness index (SI, photo plethysmography) from baseline to week 1
Time Frame
1 week
Title
difference in Arterial stiffness index (SI)
Description
difference in Arterial stiffness index (SI, photo plethysmography) from baseline to week 12
Time Frame
12 weeks
Title
difference in Reflection index
Description
difference in Reflection index (photo plethysmography) from baseline to week 1
Time Frame
1 week
Title
difference in Reflection index
Description
difference in Reflection index (photo plethysmography) from baseline to week 12
Time Frame
12 weeks
Title
difference in Brain natriuretic peptide (BNP)
Description
difference in Brain natriuretic peptide (BNP) from baseline to week 1
Time Frame
1 week
Title
difference in Brain natriuretic peptide (BNP)
Description
difference in Brain natriuretic peptide (BNP) from baseline to week 12
Time Frame
12 weeks
Title
difference in High sensitive troponin I (hs TnI)
Description
difference in High sensitive troponin I (hs TnI) from baseline to week 1
Time Frame
1 week
Title
difference in High sensitive troponin I (hs TnI)
Description
difference in High sensitive troponin I (hs TnI) from baseline to week 12
Time Frame
12 weeks
Title
difference in High sensitive C-reactive protein (hs CRP)
Description
difference in High sensitive C-reactive protein (hs CRP) from baseline to week 1
Time Frame
1 week
Title
difference in High sensitive C-reactive protein (hs CRP)
Description
difference in High sensitive C-reactive protein (hs CRP) from baseline to week 12
Time Frame
12 weeks
Title
difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with eGFR 45-59 ml/min/1.73 m²
Description
difference in E/E' ratio (noninvasive surrogate marker for left ventricular diastolic function (LVEDP) measured by 2D-echocardiography) between 12 weeks after baseline and at baseline in the subgroup of patients with eGFR 45-59 ml/min/1.73 m²
Time Frame
12 weeks
Title
difference in E/E' ratio (change from baseline (V1) to 12 weeks follow-up) in the subgroup of patients with HbA1c 6.5%-6.9%
Description
difference in E/E' ratio (noninvasive surrogate marker for left ventricular diastolic function (LVEDP) measured by 2D-echocardiography) between 12 weeks after baseline and at baseline in the subgroup of patients with with HbA1c 6.5%-6.9%
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
difference in biomarkers of cardiac diseases
Description
changes between baseline and follow-up after 1 week in biomarkers of cardiac diseases
Time Frame
1 week
Title
difference in biomarkers of cardiac diseases
Description
changes between baseline and follow-up after 12 weeks in biomarkers of cardiac diseases
Time Frame
12 weeks
Title
difference in biomarkers of vascular diseases
Description
changes between baseline and follow-up after 1 week in biomarkers of vascular diseases
Time Frame
1 week
Title
difference in biomarkers of vascular diseases
Description
changes between baseline and follow-up after 12 weeks in biomarkers of vascular diseases
Time Frame
12 weeks
Title
difference in biomarkers of metabolic/diabetic status
Description
changes between baseline and follow-up after 1 week in biomarkers of metabolic/diabetic status
Time Frame
1 week
Title
difference in biomarkers of metabolic/diabetic status
Description
changes between baseline and follow-up after 12 weeks in biomarkers of metabolic/diabetic status
Time Frame
12 weeks
Title
changes in vascular/endothelial function
Description
changes between baseline and follow-up after 1 week in vascular/endothelial function
Time Frame
1 week
Title
changes in vascular/endothelial function
Description
changes between baseline and follow-up after 12 weeks in vascular/endothelial function
Time Frame
12 weeks
Title
changes in carotid atherosclerosis
Description
changes between baseline and follow-up after 1 week in carotid atherosclerosis
Time Frame
1 week
Title
changes in carotid atherosclerosis
Description
changes between baseline and follow-up after 12 weeks in carotid atherosclerosis
Time Frame
12 weeks
Title
changes in pulmonary function
Description
changes between baseline and follow-up after 1 week in pulmonary function
Time Frame
1 week
Title
changes in pulmonary function
Description
changes between baseline and follow-up after 12 weeks in pulmonary function
Time Frame
12 weeks
Title
changes in ophthalmological diseases
Description
changes between baseline and follow-up after 1 week in ophthalmological diseases
Time Frame
1 week
Title
changes in ophthalmological diseases
Description
changes between baseline and follow-up after 12 weeks in ophthalmological diseases
Time Frame
12 weeks
Title
changes in psychosomatic diseases
Description
changes between baseline and follow-up after 1 week in psychosomatic diseases
Time Frame
1 week
Title
changes in psychosomatic diseases
Description
changes between baseline and follow-up after 12 weeks in psychosomatic diseases
Time Frame
12 weeks
Title
association analysis for selected SNPs
Description
association analysis for selected SNPs (measured at baseline)
Time Frame
baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
84 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects meeting all of the following criteria at visit 0 (screening) will be considered for admission to the trial: Diagnosis of type 2-diabetes mellitus with stable glucose-lowering background therapy and/or dietetic treatment for at least 12 weeks In subjects without glucose-lowering background therapy: the application of Metformin was considered to be unsuitable due to drug intolerance HbA1c level of ≥6.5% and ≤10.0% at visit 0 (screening) for subjects on antidiabetic background therapy or HbA1c level of ≥6.5% and ≤9.0% for drug-naïve subjects with dietetic treatment Diastolic cardiac dysfunction E/E' ratio ≥8 (2D-echocardiography) Age 18 - 84 years BMI ≤ 45 kg/m² (Body Mass Index) For women: post-menopausal for more than 12 months without an alternative medical cause can participate in the trial. Women with childbearing potential can only participate, if they are surgically sterile or a negative pregnancy test (serum or urine) is available at visit 1 and they are willing to practice highly effective birth control method during trial. Reliable highly effective contraception comprises combined (estrogen and progesteron containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) progesteron-only hormonal contraception associated with inhibition of ovaluation (oral, injectable, implantable) intrauterine device (IUD) intrauterine hormone-releasing system (IUS) bilateral tubal occlusion vasectomised partner (provided that partner is the sole sexual partner and that the vasectomised partner has received medical assessment of the surgical success) sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Ability of subject to understand nature, importance and individual consequences of clinical trial Signed and dated informed consent of the subject must be available before start of any specific trial procedures which is consistent with ICH-GCP guidelines and local legislation Exclusion Criteria: Subjects presenting with any of the following criteria at visit 0 (screening) will not be included in the trial: Pretreatment with empagliflozin or other SGLT2 inhibitor within the last 3 months Pretreatment with known inducers of UGT enzymes Uncontrolled hyperglycemia with a glucose level > 240 mg/dl (>13.3 mmol/L) after an overnight fast Impaired renal function, defined as eGFR <45 ml/min/1.73 m² of body-surface-area End-stage renal failure or dialysis Severe hepatic dysfunction, defined by serum levels of either SGPT, SGOT, or alkaline phosphatase above 3 x upper limit of normal (ULN) Acute urinary tract infection (UTI) Known acute genital infection (GI) Symptomatic hypotension Hematocrit above the upper limit of the reference range Hypoglycemic tendencies Severe PAD (Fontaine classification Stage IIb - IV) Medical history of cancer and/or treatment for cancer within the last 5 years, subjects basalioma can be included in the study Medical history of pancreatitis or surgery on pancreas Known ketoacidosis (in the past) Acute febrile disease NYHA classification III - IV Pregnant and/or nursing women at visit 1 (baseline) Acute coronary syndrome, stroke or TIA within the last 2 months Planned cardiac surgery or angioplasty within 3 months Gastrointestinal surgeries that induce chronic malabsorption Blood dyscrasia or any disorders causing hemolysis or unstable Red Blood Cells (e.g. malaria, babesiosis, hemolytic anemia) History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product Alcohol or drug abuse within the last 3 months that would interfere with trial participation Medical or psychological conditions that would jeopardize an adequate and orderly completion of the trial (at visit 0 (screening) or at visit 1 (baseline)) Medical condition that does not allow enrollment in the trial at visit 1 (baseline) Current treatment with systemic steroids or change in dosage of thyroid hormones within the last 6 weeks or any other uncontrolled endocrine disorder except type 2 diabetes mellitus Hereditary glucose intolerance, galactose intolerance, Lapp-lactase deficiency or glucose-galactose-malabsorption Intake of an investigational drug in another trial within 30 days prior to intake of study medication in this trial or participating in another trial (involving an investigational drug and/or follow-up)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philipp Wild, MD, MSc
Organizational Affiliation
Johannes Gutenberg University Mainz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Zentrum für Kardiologie, Präventive Kardiologie und Medizinische Prävention
City
Mainz
ZIP/Postal Code
55131
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
34939776
Citation
Junger C, Prochaska JH, Gori T, Schulz A, Binder H, Daiber A, Koeck T, Rapp S, Lackner KJ, Munzel T, Wild PS. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study. J Cardiovasc Med (Hagerstown). 2022 Mar 1;23(3):191-197. doi: 10.2459/JCM.0000000000001267.
Results Reference
derived

Learn more about this trial

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

We'll reach out to this number within 24 hrs